While the Kennedy pathway is required for normal cell function and thus targeting PCYT1A in cancer may lead to unfavorable side effects, two groups of adult patients with a functional mutation in PCYT1A have been identified [42,53]. This evidence concerns the gene PCYT1A and cancer.